除二肽基肽酶4抑制剂外,口服降糖药与类天疱疮无关:芬兰全国性病例对照研究
该芬兰全国性病例对照研究分析了3397例类天疱疮患者与12941例基底细胞癌对照,评估除二肽基肽酶4抑制剂、二甲双胍和胰岛素外的降糖药与类天疱疮的关联。结果显示19.6%的类天疱疮患者患有2型糖尿病,所研究的降糖药均与类天疱疮风险增加无关。作者认为这些药物在该人群中可安全使用,但推广至其他人群需进一步研究。
要点
- 19.6%的类天疱疮患者患有2型糖尿病。
- 所研究的降糖药均未与类天疱疮风险增加相关。
- 作者认为这些降糖药在芬兰人群中可安全使用,但推广需进一步研究。
核心结论
- 所研究的降糖药在芬兰患者数据库中与类天疱疮风险增加无关,表明它们在该人群中可安全使用。
- 将这些结果推广到其他人群将需要进一步研究。
研究设计与样本
- 芬兰全国性注册数据的病例对照研究,纳入3397例类天疱疮患者和12941例基底细胞癌对照。
主要发现
- 19.6%的类天疱疮患者患有2型糖尿病。
- 所研究的降糖药(排除二肽基肽酶4抑制剂、二甲双胍和胰岛素)均未与类天疱疮风险增加相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于是注册登记研究,无法核实诊断的准确性。
- 无法分析胰高血糖素样肽1受体激动剂使用者的类天疱疮风险。
- 将结果推广到其他人群将需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dipeptidyl peptidase 4 inhibitors (DPP4is) used to treat diabetes have been reported to be associated with an increased risk of bullous pemphigoid (BP). There are no previous reports analyzing the risk of BP in patients who are using other diabetes medications. OBJECTIVE: To evaluate the association between diabetes medications other than DPP4i and development of BP. METHODS: We investigated the prevalence of diabetes among patients with BP and the association between the use of diabetes drugs (excluding DPP4i, metformin, and insulin) and BP by analyzing national Finnish registry data for 3397 patients with BP and 12,941 patients with basal cell carcinoma as controls. RESULTS: Our results show that 19.6% of patients with BP have type 2 diabetes. Use of none of the investigated medications was associated with an increased risk of BP. LIMITATIONS: Because this was a registry-based study, it was not possible to verify the accuracy of the diagnoses. The risk of BP in users of glucagon-like peptide 1 receptor agonists could not be analyzed. CONCLUSION: Our study shows that the investigated diabetes drugs are not associated with an increased risk of BP in a Finnish patient database, indicating they can be safely used in this population. Generalization of these results to other populations will require further study.
引用
- Varpuluoma O, Försti AK, Jokelainen J, et al. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study. J Am Acad Dermatol. 2018. PMID: 29803903. doi:10.1016/j.jaad.2018.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。